# ATX-MS-1467 in Multiple Sclerosis

> **NCT01973491** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 37 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** ATX-MS-1467

## Key facts

- **NCT ID:** NCT01973491
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-28
- **Primary completion:** 2016-04-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973491, "ATX-MS-1467 in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01973491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*